← Back to Screener
Revelation Biosciences, Inc. Common Stock (REVB)
Price$1.09
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-83.72%
Price vs S&P 500 (4W)-7.20%
VGM Score22.47
Market Capitalization$4.28M
All Metrics
Book Value / Share (Quarterly)$3.32
P/TBV (Annual)4.01x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.24
Price vs S&P 500 (YTD)-76.72%
EPS (TTM)$-17.64
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-17.64
EPS (Annual)$-14.36
ROI (Annual)-100.59%
Cash / Share (Quarterly)$3.61
ROA (Last FY)-76.96%
EBITD / Share (TTM)$-7.17
ROE (5Y Avg)-305.08%
Cash Flow / Share (Annual)$-5.22
P/B Ratio0.33x
P/B Ratio (Quarterly)0.34x
Net Income / Employee (Annual)$-1,114,200
ROA (TTM)-87.99%
EV / EBITDA (TTM)-11.03x
EPS Incl Extra (Annual)$-14.36
Current Ratio (Annual)5.41x
Quick Ratio (Quarterly)9.96x
3-Month Avg Trading Volume0.48M
52-Week Price Return-89.63%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.40
52-Week High$13.80
EPS Excl Extra (Annual)$-14.36
26-Week Price Return-67.79%
Quick Ratio (Annual)5.38x
13-Week Price Return-17.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.02x
Enterprise Value$-9.83M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.76
3-Month Return Std Dev55.89%
Net Income / Employee (TTM)$-1,234,000
ROE (Last FY)-100.59%
EPS Basic Excl Extra (Annual)$-14.36
EV / Free Cash Flow (TTM)-10.86x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-17.64
ROI (TTM)-107.66%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.54
Price vs S&P 500 (52W)-117.84%
Year-to-Date Return-65.78%
5-Day Price Return2.34%
EPS Normalized (Annual)$-14.36
ROA (5Y Avg)-217.77%
Month-to-Date Return-3.10%
Cash Flow / Share (TTM)$0.23
EBITD / Share (Annual)$-14.57
ROI (5Y Avg)-305.08%
EPS Basic Excl Extra (TTM)$-17.64
P/TBV (Quarterly)0.48x
P/B Ratio (Annual)0.53x
Book Value / Share (Annual)$5.59
Price vs S&P 500 (13W)-27.42%
Beta-0.11x
Revenue / Share (TTM)$0.00
ROE (TTM)-107.66%
52-Week Low$0.88
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-2.71est. -1.17
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
REVBRevelation Biosciences, Inc. Common Stock | — | — | D | $1.09 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Revelation Biosciences is a clinical-stage biotech company developing immunology-based treatments using Gemini, a proprietary TLR4 agonist designed to modulate inflammatory responses for therapeutic benefit. The company's pipeline includes three Gemini-based programs: Gemini-SSI for surgical site infection prevention, Gemini-AKI for acute kidney injury prevention, and Gemini-CKD for chronic kidney disease treatment.